Related Experiment Videos
Movement disorders: a step in the right direction
1Department of Neurology, Mount Sinai School of Medicine, New York, NY, USA. Warren.olanow@mssm.edu
The Lancet. Neurology
|December 20, 2005
Summary
No abstract available in PubMed .
Related Concept Videos
You might also read
Related Articles
Articles linked to this work by shared authors, journal, and citation graph.
Sort by
Same author
A double-blind, controlled trial of circadian effective light therapy in patients with Parkinson's disease.
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2025
Same author
CVN424, a GPR6 inverse agonist, for Parkinson's disease and motor fluctuations: a double-blind, randomized, phase 2 trial.
EClinicalMedicine·2024
Same author
Continuous Levodopa Delivery with an Intraoral Micropump System: An Open-Label Pharmacokinetics and Clinical Study.
Movement disorders : official journal of the Movement Disorder Society·2024
Same author
Safety and efficacy of continuous subcutaneous levodopa-carbidopa infusion (ND0612) for Parkinson's disease with motor fluctuations (BouNDless): a phase 3, randomised, double-blind, double-dummy, multicentre trial.
The Lancet. Neurology·2024
Same author
A Phase I, Randomized, SAD, MAD, and PK Study of Risvodetinib in Older Adults and Parkinson's Disease.
Journal of Parkinson's disease·2024
Same author
Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
The Lancet. Neurology·2023
Same journal
Resolution of expression of concern-Serotonergic pathology and disease burden in the premotor and motor phase of A53T α-synuclein parkinsonism: a cross-sectional study.
The Lancet. Neurology·2026
Same journal
UCL Queen Square Institute of Neurology: 75 years of innovation.
The Lancet. Neurology·2026
Same journal
Epstein-Barr virus and multiple sclerosis: from associations to mechanisms to potential therapies.
The Lancet. Neurology·2026